ER-positive and BRCA2-mutated breast cancer: a literature review
Pu‐Chun Li, Yifan Zhu, Wen‐Ming Cao, Bei Li
Abstract
BRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate cancer). Almost 70-80% of BRCA2-mutated BC are estrogen receptor (ER)-positive, which is a particular type of ER-positive BC that differs from sporadic ER-positive BC. This article reviews the clinicopathological features, treatment, and prognosis of ER-positive and BRCA2-mutated BC to provide a reference for clinical decision-making.
Topics & Concepts
Breast cancerMedicineOncologyInternal medicineCancerBioinformaticsCancer researchBiologyBRCA gene mutations in cancerAdvanced Breast Cancer TherapiesPARP inhibition in cancer therapy